<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group>
<journal-title>PLoS ONE</journal-title></journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, USA</publisher-loc></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">PONE-D-13-22342</article-id>
<article-id pub-id-type="doi">10.1371/journal.pone.0078254</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories>
<title-group>
<article-title>RTK/ERK Pathway under Natural Selection Associated with Prostate Cancer</article-title>
<alt-title alt-title-type="running-head">RTK/ERK Pathway and Prostate Cancer</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes" xlink:type="simple"><name name-style="western"><surname>Chen</surname><given-names>Yang</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib>
<contrib contrib-type="author" equal-contrib="yes" xlink:type="simple"><name name-style="western"><surname>Xin</surname><given-names>Xianxiang</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib>
<contrib contrib-type="author" equal-contrib="yes" xlink:type="simple"><name name-style="western"><surname>Li</surname><given-names>Jie</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Xu</surname><given-names>Jianfeng</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref><xref ref-type="aff" rid="aff7"><sup>7</sup></xref><xref ref-type="aff" rid="aff8"><sup>8</sup></xref><xref ref-type="aff" rid="aff9"><sup>9</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Yu</surname><given-names>Xiaoxiang</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Li</surname><given-names>Tianyu</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mo</surname><given-names>Zengnan</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Hu</surname><given-names>Yanling</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib>
</contrib-group>
<aff id="aff1"><label>1</label><addr-line>Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China</addr-line></aff>
<aff id="aff2"><label>2</label><addr-line>Medical Research Center, Guangxi Medical University, Nanning, Guangxi, China</addr-line></aff>
<aff id="aff3"><label>3</label><addr-line>Department of Urology and Nephrology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China</addr-line></aff>
<aff id="aff4"><label>4</label><addr-line>Department of Urology, the 303rd Hospital of Chinese People's Liberation Army, Nanning, Guangxi Zhuang Autonomous Region, China</addr-line></aff>
<aff id="aff5"><label>5</label><addr-line>Research Center for Guangxi Reproductive Medicine, First Affiliated Hospital of Guangxi Medical University, Guangxi Zhuang Autonomous Region, China</addr-line></aff>
<aff id="aff6"><label>6</label><addr-line>Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China</addr-line></aff>
<aff id="aff7"><label>7</label><addr-line>Fudan Center for Genetic Epidemiology, School of Life Sciences, Fudan University, Shanghai, China</addr-line></aff>
<aff id="aff8"><label>8</label><addr-line>State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China</addr-line></aff>
<aff id="aff9"><label>9</label><addr-line>Center for Cancer Genomics, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States of America</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple"><name name-style="western"><surname>Migliaccio</surname><given-names>Antimo</given-names></name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/></contrib>
</contrib-group>
<aff id="edit1"><addr-line>II Università di Napoli, Italy</addr-line></aff>
<author-notes>
<corresp id="cor1">* E-mail: <email xlink:type="simple">zengnanmo@hotmail.com</email> (ZNM); <email xlink:type="simple">ylhupost@163.com</email> (YHL)</corresp>
<fn fn-type="conflict"><p>The authors have declared that no competing interests exist.</p></fn>
<fn fn-type="con"><p>Conceived and designed the experiments: YC XXX JL ZNM YLH. Performed the experiments: YC XXX JL ZNM YLH. Analyzed the data: YC XXX JL XXY TYL. Contributed reagents/materials/analysis tools: JFX . Wrote the paper: YC XXX JL. Provided significant advice for the manuscript: JFX XXY TYL. Provided the original data and materials: JFX.</p></fn>
</author-notes>
<pub-date pub-type="collection"><year>2013</year></pub-date>
<pub-date pub-type="epub"><day>4</day><month>11</month><year>2013</year></pub-date>
<volume>8</volume>
<issue>11</issue>
<elocation-id>e78254</elocation-id>
<history>
<date date-type="received"><day>29</day><month>5</month><year>2013</year></date>
<date date-type="accepted"><day>10</day><month>9</month><year>2013</year></date>
</history>
<permissions>
<copyright-year>2013</copyright-year>
<copyright-holder>Chen et al</copyright-holder><license xlink:type="simple"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions>
<abstract>
<p>Prostate cancer (PCa) is a global disease causing large numbers of deaths every year. Recent studies have indicated the RTK/ERK pathway might be a key pathway in the development of PCa. However, the exact association and evolution-based mechanism remain unclear. This study was conducted by combining genotypic and phenotypic data from the Chinese Consortium for Prostate Cancer Genetics (ChinaPCa) with related databases such as the HapMap Project and Genevar. In this analysis, expression of quantitative trait loci (eQTLs) analysis, natural selection and gene-based pathway analysis were involved. The pathway analysis confirmed the positive relationship between PCa risk and several key genes. In addition, combined with the natural selection, it seems that 4 genes (EGFR, ERBB2, PTK2, and RAF1) with five SNPs (rs11238349, rs17172438, rs984654, rs11773818, and rs17172432) especially rs17172432, might be pivotal factors in the development of PCa. The results indicate that the RTK/ERK pathway under natural selection is a key link in PCa risk. The joint effect of the genes and loci with positive selection might be one reason for the development of PCa. Dealing with all the factors simultaneously might give insight into prevention and aid in predicting the success of potential therapies for PCa.</p>
</abstract>
<funding-group><funding-statement>This study was supported by grants from National Program on Key Basic Research Project (973 Program) (2012CB518303), the National Natural Science Foundation of China (81060213, 81272853), Guangxi Natural Science Foundation (2011GXNSFB018100) and Postdoctoral Sustentation Fund of China (2012M511886). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="8"/></counts></article-meta>
</front>
<body><sec id="s1">
<title>Introduction</title>
<p>As one of the most destructive cancers worldwide <xref ref-type="bibr" rid="pone.0078254-Parkin1">[1]</xref>, prostate cancer (PCa) is increasing according to recent cancer statistics in the United States <xref ref-type="bibr" rid="pone.0078254-Jemal1">[2]</xref>–<xref ref-type="bibr" rid="pone.0078254-Jemal2">[4]</xref>. Although the death rates continuing to decline (declining by 1.9% from 2000 to 2008 per year), 238,590 new cases might be discovered, with a mortality rate of 12.5% <xref ref-type="bibr" rid="pone.0078254-Siegel2">[5]</xref>. In Europe, the incidence has tripled in the last 40 years, with about 328,000 men diagnosed with prostate cancer in 2008 <xref ref-type="bibr" rid="pone.0078254-Ferlay1">[6]</xref>. In order to identify the potential role of genetic factors in the development of PCa, several recent studies have been based on analysis at the gene level. Recently, one of the most effective methods, a genome-wide association study (GWAS), was used to conduct high-throughput SNP polymorphism analysis that could reveal significant loci that influence the disease. However, at the same time, with its strict standards and SNP-based analysis, some potential useful information might be ignored. So conducting the further study, which could reveal more comprehensive information, seemed to be important.</p>
<p>Considering the complexity of the factors inducing disease, especially cancer, the interlacing signaling pathways and cell signal transmission involved in biological activities such as cell survival, development, and apoptosis <xref ref-type="bibr" rid="pone.0078254-Shih1">[7]</xref>–<xref ref-type="bibr" rid="pone.0078254-Jung1">[9]</xref> might make the pathogenesis clearer. As one of the crucial cancer pathways, the RTK/ERK pathway is said to be one of the important links in cancer's development, containing a number of genes (EGFR, EGF, CCND1, MAPK3, etc.). In this pathway, receptor tyrosine kinases (RTKs) represent enzyme-linked receptors, which regulate cell proliferation and differentiation, promote cell migration and survival and modulate cellular metabolism in response to extracellular cues <xref ref-type="bibr" rid="pone.0078254-McKay1">[10]</xref>–<xref ref-type="bibr" rid="pone.0078254-Malumbres1">[12]</xref>. However, in order to arouse most RTK pathway functions, the essential effector mitogen-activated protein kinase (MAPK) cascade needs to be activated, composed of the Raf, MEK, and extracellular signal-regulated kinase (ERK) kinases (known as the ERK cascade). With activation of the MAPK cascade, a signal from a receptor on the surface of the cell to the DNA in the nucleus of the cell is transferred by proteins influencing regulation, transcription, and synthesis of the genes <xref ref-type="bibr" rid="pone.0078254-Orton1">[13]</xref>, <xref ref-type="bibr" rid="pone.0078254-Pawson1">[14]</xref>. So the growth of an organism, angiogenesis, and carcinogenesis are all involved with the critical functions of the RTK pathway.</p>
<p>PCa is one of the most common malignancies in the world. Its high rate of morbidity and mortality bring about enormous losses. So studying the pathogenesis of PCa seems extremely urgent, including determining which genetic factors might be significant in the process. Summarizing recent studies, the pathway might be a vital factor in the development and progression of PCa. In 2007, Caraglia M et al. <xref ref-type="bibr" rid="pone.0078254-Caraglia1">[15]</xref> found that zoledronic acid (ZOL) and R115777 farnesyltransferase inhibitor (FTI, Zarnestra) were synergistic in destroying the Ras/Erk and Akt survival pathways and decreasing the phosphorylation of both mitochondrial bcl-2 and bad proteins, and caspase activation, which led to both growth inhibition and apoptosis in prostate adenocarcinoma cells. Moreover, Milone et al. <xref ref-type="bibr" rid="pone.0078254-Milone1">[16]</xref> studied the ZOL further, which suggested the p38-MAPK pathway played a key role in inducing a more aggressive and invasive phenotype and resisting to the ZOL. In addition, our previous path enrichment and gene meta-analysis by Gene Set Enrichment Analysis (GSEA) <xref ref-type="bibr" rid="pone.0078254-Ning1">[17]</xref> suggested that significantly expressed genes were located on the RTK/ERK pathway.</p>
<p>Meanwhile, recent studies have discovered natural selection in genes and networks based on populations <xref ref-type="bibr" rid="pone.0078254-Kelley1">[18]</xref>–<xref ref-type="bibr" rid="pone.0078254-AcuaAlonzo1">[19]</xref>, which gave a new view at the evolutionary level into the pathogenesis of diseases. However, no related studies have revealed the potential relationship between the RTK/ERK pathway under natural selection and PCa risk. Prompted by this, the present study was conducted.</p>
<p>This study was based on the key role function of the RTK/ERK pathway, the HapMap database and our own GWA study data about PCa risk. In this analysis, we explored the pathway via several methods: (1) association analysis between gene polymorphisms in the RTK-ERK pathway and PCa; (2) gene-based pathway testing; and (3) natural positive selection and expression quantitative trait loci (eQTLs) analysis. Combining all of these effective analyses, this study might give us a more comprehensive understanding of the RTK/ERK pathway based on genes and SNP analysis, which would help us discover potential crucial loci or genes and give a wide view on the treatment, prevention, and forecasting of Pca.</p>
</sec><sec id="s2" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="s2a">
<title>Study subjects</title>
<p>The analyses in this study were mainly based on the Chinese Consortium for Prostate Cancer Genetics (ChinaPCa) GWAS, the HapMap Project (<ext-link ext-link-type="uri" xlink:href="http://www.hapmap.org" xlink:type="simple">http://www.hapmap.org</ext-link>), and other databases (NCBI36). Subjects in the ChinaPCA were male Han Chinese recruited from the southeastern in China. They came from different areas, including Shanghai, Suzhou, Guangxi, Nanjing, etc. There were 1417 hospital-based cases that were confirmed to have primary prostate cancer histologically and 1008 health controls that had undergone routine physical examination in local hospitals. Their characteristics are showed in the <xref ref-type="table" rid="pone-0078254-t001">Table 1</xref>. A blood sample was obtained from each subject for DNA extraction when consent was obtained. On the basis of our pathway analysis, 50,459 polymorphic SNPs were potentially involved. All genes were extended 100 kb from beginning to end in order to ensure all loci in the pathway were included. Comprehensive epidemiological and clinical data were collected with standardized questionnaires and from the associated PCa diagnosis. Essential information was included, such as age, the level of the PSA, the record of the cancer, and other related datum. All the details were given in Jianfeng Xu et al. <xref ref-type="bibr" rid="pone.0078254-Xu1">[20]</xref>.</p>
<table-wrap id="pone-0078254-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0078254.t001</object-id><label>Table 1</label><caption>
<title>Characteristics of the subjects included in this analysis.</title>
</caption><alternatives><graphic id="pone-0078254-t001-1" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0078254.t001" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">case (n = 1417)</td>
<td align="left" rowspan="1" colspan="1">control (n = 1008)</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">Age (mean±SD)</td>
<td align="left" rowspan="1" colspan="1">71.3±8.1</td>
<td align="left" rowspan="1" colspan="1">62.1±1.0</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Classification of PSA, n (%)</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">≤4.0</td>
<td align="left" rowspan="1" colspan="1">55 (4.1%)</td>
<td align="left" rowspan="1" colspan="1">965 (95.9%)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">&gt;4.0, &lt;10</td>
<td align="left" rowspan="1" colspan="1">186 (13.9%)</td>
<td align="left" rowspan="1" colspan="1">32 (3.2%)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">≥10</td>
<td align="left" rowspan="1" colspan="1">1098 (82.0%)</td>
<td align="left" rowspan="1" colspan="1">9 (0.9%)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Missing</td>
<td align="left" rowspan="1" colspan="1">78</td>
<td align="left" rowspan="1" colspan="1">2</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Gleason score, n (%)</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">&lt;7</td>
<td align="left" rowspan="1" colspan="1">355 (26.3%)</td>
<td align="left" rowspan="1" colspan="1">NA</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">≥7</td>
<td align="left" rowspan="1" colspan="1">993 (73.7%)</td>
<td align="left" rowspan="1" colspan="1">NA</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Missing</td>
<td align="left" rowspan="1" colspan="1">69</td>
<td align="left" rowspan="1" colspan="1">NA</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Clinical stage, n (%)</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Stage (0, I, II)</td>
<td align="left" rowspan="1" colspan="1">727 (59.7%)</td>
<td align="left" rowspan="1" colspan="1">NA</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Stage (III, IV)</td>
<td align="left" rowspan="1" colspan="1">490 (40.3%)</td>
<td align="left" rowspan="1" colspan="1">NA</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">N-stage(0)</td>
<td align="left" rowspan="1" colspan="1">759 (67.3%)</td>
<td align="left" rowspan="1" colspan="1">NA</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">N-stage(≥1)</td>
<td align="left" rowspan="1" colspan="1">369 (32.7%)</td>
<td align="left" rowspan="1" colspan="1">NA</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">M-stage(0)</td>
<td align="left" rowspan="1" colspan="1">810 (64.8%)</td>
<td align="left" rowspan="1" colspan="1">NA</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">M-stage(≥1)</td>
<td align="left" rowspan="1" colspan="1">440 (35.2%)</td>
<td align="left" rowspan="1" colspan="1">NA</td>
</tr>
</tbody>
</table>
</alternatives><table-wrap-foot><fn id="nt101"><label/><p>• all the information are collected at the moment of the cases diagnosed and controls recruited.</p></fn></table-wrap-foot></table-wrap>
<p>In addition, the HapMap Project Phases II and III were also applied in the study, combining them with the ChinaPCA. Considering the close affinity between similar genes, we selected 60 unrelated samples for our analysis for the CEU and YRI. Meanwhile, the CHB (Han Chinese from Beijing) and JPT (Japanese from Tokyo) were pooled with 89 non-affinity Asian individuals, referred to as the ASN. In this study, the numbers of SNPs in each population were 791,208 (ASN), 849,575 (CEU), and 885,926 (YRI) <xref ref-type="bibr" rid="pone.0078254-International1">[21]</xref>–<xref ref-type="bibr" rid="pone.0078254-Voight1">[23]</xref>.</p>
</sec><sec id="s2b">
<title>Associations between gene polymorphisms of the RTKs-ERK pathway and prostate cancer</title>
<p>As an important pathway in the development of cancer, the RTKs-ERK pathway could easily induce cancer when its proteins become mutated. Many genes are known to be involved in this pathway, with some related ones as yet undiscovered. In our study, we included almost all the genes known in the pathway for analysis, comprising 40 genes: EGF, EGFR, PDGF, VEGF, MAP2K1, CCND1, and others located from every chromosome. In order to ensure all the SNPs in the pathway were included, we amplified the length of the genes in both directions for 100 kb. Finally, nearly 50,000 SNPs were involved. With these SNPs, systematic association tests for the risk of PCa were conducted, including single-SNP association tests and a gene-based pathway association test. A logistic regression model implemented in Plink <xref ref-type="bibr" rid="pone.0078254-Purcell1">[24]</xref> was applied to test the associations between the selective SNP polymorphisms and PCa with the covariate of age.</p>
<p>In the gene-based pathway test, the adaptive rank truncated product (ARTP) method was applied. ARTP method was proposed by Yu K et al. <xref ref-type="bibr" rid="pone.0078254-Yu1">[25]</xref>, and the method was based on the adaptive rank truncated product statistic to combine evidence of associations over different SNPs and genes within a biological pathway. It mainly could be divided into two steps: first, the association evidence between a gene and the outcome was obtained with the standardized summary; second, combine these gene-level P-values into a test statistic for the disease-pathway association. As a powerful statistical method, ARTP could remedy the shortcomings of the rank truncated product (RTP) method, in which the product of K most significant P-values were used as the summary statistic <xref ref-type="bibr" rid="pone.0078254-Dudbridge1">[26]</xref>. According to the method, the potential significant association between the genes, pathway, and related diseases could be revealed. In this study, the SNPs with the significant association (<italic>P</italic>&lt;0.05) were collected in the gene-based ARTP analysis. In addition, 10,000 permutations were included in the analysis in order to make the statistics more convincing.</p>
</sec><sec id="s2c">
<title>Natural positive selection loci and eQTL analysis</title>
<p>Although the GWA study indicated that a number of SNPs were associated with prostate cancer, an area analysis of the haplotype could not be included, which might neglect possible related loci. However, the interactions in terms of the functional consequences and evolutionary history of these loci remain largely unknown. Recently, several studies have proposed natural positive selection based on haplotype analysis in various populations <xref ref-type="bibr" rid="pone.0078254-Raj1">[27]</xref>–<xref ref-type="bibr" rid="pone.0078254-Metspalu1">[28]</xref>. Candidate regions that are experiencing positive selection could be identified by a number of sophisticated statistical methods. In this study, we applied the integrated haplotype score (iHs), which was developed in 2006 <xref ref-type="bibr" rid="pone.0078254-Voight1">[23]</xref>, <xref ref-type="bibr" rid="pone.0078254-Nash1">[29]</xref>. This test statistic was said to select potential positive selection loci with an empirical threshold of 2 or 1.65. iHS score is derived from the extended haplotype homozygosity statistic (EHH) <xref ref-type="bibr" rid="pone.0078254-Sabeti1">[30]</xref>, which measures the decay of the identity of haplotypes that carry a specified “core” allele at one end. It is said that when an allele rises rapidly in frequency due to strong selection, it tends to have high levels of haplotype homozygosity, extending much further than expected under a neutral model. Combining with the EHH, Voight et al. <xref ref-type="bibr" rid="pone.0078254-Voight1">[23]</xref> proposed the integrated EHH (iHH), which is divided into iHH<sub>A</sub> and iHH<sub>B</sub> with the limitation of computing with respect to an ancestral or derived core allele. In addition, considering the influence of allele frequency on the core SNP, Voight et al. improved the data analysis. And iHS score was conducted with all SNPs with minor allele frequency &gt;5% that were treated as core SNPs. As to the results, both extremely positive and extremely negative iHS scores would be potentially interesting.</p>
<p>In our study, the web-based tool Haplotter <xref ref-type="bibr" rid="pone.0078254-Sabeti1">[30]</xref> was applied to identify iHS scores from the HapMap phase II for three different populations (ASN, CEU and YRI). Considering the various physical locations in the different databases, the number of rs for all the SNP in the RTKs-ERK pathway was selected. According to these findings, iHs values derived with the HapMap Project phase II were confirmed. In addition, Plink was used to explore the association between the ChinaPCA and matched genotypes in all the samples in the pathway. A logistic regression model was used with the PSA value and the covariate was age. On the basis of the SNP (rs), the iHS scores and P-values for the associations were matched. The SNPs, which were said to be significant associations, were collected. Meanwhile, considering the robustness of the selection signals, we continued to conduct a gene-based approach. In this analysis, a window of 50 SNPs centered on each gene closest to the index SNP was created. The candidate targets of selection were defined to be in the upper 10% of the empirical distribution for number of significant SNPs.</p>
<p>When it came to the expression quantitative trait loci (eQTLs) analysis, not only cis- but tran-, the left SNPs with |iHs|&gt;2 were included. Single cis-eQTL considered all association signals from SNPs within 1 Mb up- and down-stream, and trans-eQTLs were identified as being associated with SNPs located greater than 1 Mb from the probe set. The correlation with nearby gene expression was available in the eQTL database Genevar as measured by probes (<ext-link ext-link-type="uri" xlink:href="http://www.sanger.ac.uk/resources/software/genevar/" xlink:type="simple">http://www.sanger.ac.uk/resources/software/genevar/</ext-link>). The HapMap III with 726 individuals (CEU, CHB, GIH, JPT, LWK, MEX, MKK, and YRI), Geneva with 75 individuals (three types of samples: fibroblast, lymphoblastoid cell line, and T cell) and MuTHER healthy female twins with three tissue types (166 adipose, 156 lymphoblastoid cell line, and 160 skin) were collected in this analysis. A linear regression model was used take the distribution of normalized expression levels between genotypes into consideration. And a significance threshold of <italic>P</italic>&lt;0.05 with 10,000-fold permutations was applied to avoid false positive associations.</p>
<p>All analyses were performed using Statistical Analysis System (SAS) software (version 9.0; SAS Institute, Cary, NC, USA) and Plink. All statistical tests were two sided.</p>
</sec></sec><sec id="s3">
<title>Results</title>
<p>As a key pathway in carcinogenesis, the RTKs-ERK pathway could influence the cell, tissue, and organism directly by mutations in its proteins, which would block normal signal transmission from the extracellular milieu to the DNA. In recent years, many studies have focused on this pathway for the pathogenesis and treatment of diseases, particularly cancers. On the basis of the genes and SNPs of this pathway, the study was conducted with the positive selection loci and eQTL analysis involved.</p>
<sec id="s3a">
<title>SNP-level association and gene-based rank truncated product (ARTP)</title>
<p>We tested the association between each SNP and PCa risk using a logistic regression model after adjusting for age (<xref ref-type="supplementary-material" rid="pone.0078254.s001">Table S1</xref>). The results showed that 317 loci reached the threshold value of significance (<italic>P</italic>&lt;0.05). When it came to the genes in the RTKs-ERK pathway, three SNPs (rs1815009, rs3743250, and rs3743249) in IGF1R presented with ideal <italic>P</italic>-values (2.84×10<sup>−4</sup>, 2.98×10<sup>−4</sup>, and 4.35×10<sup>−4</sup>), which were in the exon in utr-variant-3-prime. In addition, ERBB2 with six loci (rs2517959, rs2643194, rs2517960, rs2088126, rs903506, and rs2643195) and CCND3 with three loci (rs115597780, rs149917140, and rs4331978) were said to be significant in PCa risk considering their <italic>P</italic>-values.</p>
<p>After the SNP-level analysis, we tested the pathway on the basis of the gene-level ARTP method. Almost all the genes involved in the pathway were selected, with 4276 SNPs reaching significance after the logistic regression model (<italic>P</italic>&lt;0.05) with 10,000 permutations. The gene-based <italic>P</italic>-values derived from ARTP methods were significant for genes ERBB2 (<italic>P</italic> = 0.0034), PTK2 (<italic>P</italic> = 0.0043), FLT1 (<italic>P</italic> = 0.0251), RAF1 (<italic>P</italic> = 0.0173), BIRC2 (<italic>P</italic> = 0.0089), KDR (<italic>P</italic> = 0.0477), and CCND1 (<italic>P</italic> = 0.0394). Meanwhile, the pathway-level test statistic was statistically significant with a <italic>P</italic>-value of 0.0065 (<xref ref-type="table" rid="pone-0078254-t002">Table 2</xref>).</p>
<table-wrap id="pone-0078254-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0078254.t002</object-id><label>Table 2</label><caption>
<title>Results of gene-based pathway associated analysis with Adaptive rank truncated product (ARTP) method.</title>
</caption><alternatives><graphic id="pone-0078254-t002-2" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0078254.t002" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1">Genes</td>
<td align="left" rowspan="1" colspan="1"><italic>P</italic></td>
<td align="left" rowspan="1" colspan="1">Pathway <italic>P</italic></td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">IGF1R</td>
<td align="left" rowspan="1" colspan="1">0.05919</td>
<td align="left" rowspan="1" colspan="1"><bold>0.00660</bold></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>ERBB2</bold></td>
<td align="left" rowspan="1" colspan="1"><bold>0.00340</bold></td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>PTK2</bold></td>
<td align="left" rowspan="1" colspan="1"><bold>0.00430</bold></td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">CCND3</td>
<td align="left" rowspan="1" colspan="1">0.12108</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>FLT1</bold></td>
<td align="left" rowspan="1" colspan="1"><bold>0.02510</bold></td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">EGFR</td>
<td align="left" rowspan="1" colspan="1">0.12999</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">PDGFD</td>
<td align="left" rowspan="1" colspan="1">0.95091</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>RAF1</bold></td>
<td align="left" rowspan="1" colspan="1"><bold>0.01740</bold></td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">MAPK3</td>
<td align="left" rowspan="1" colspan="1">0.18758</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>BIRC2</bold></td>
<td align="left" rowspan="1" colspan="1"><bold>0.00890</bold></td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>KDR</bold></td>
<td align="left" rowspan="1" colspan="1"><bold>0.04770</bold></td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>CCND1</bold></td>
<td align="left" rowspan="1" colspan="1"><bold>0.03940</bold></td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">CCND2</td>
<td align="left" rowspan="1" colspan="1">0.58054</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">SOS1</td>
<td align="left" rowspan="1" colspan="1">0.22248</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">PDGFC</td>
<td align="left" rowspan="1" colspan="1">0.20288</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">VEGFA</td>
<td align="left" rowspan="1" colspan="1">0.4960</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">EGF</td>
<td align="left" rowspan="1" colspan="1">0.56194</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">MAP2K1</td>
<td align="left" rowspan="1" colspan="1">0.33257</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">FLT4</td>
<td align="left" rowspan="1" colspan="1">0.43616</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">MET</td>
<td align="left" rowspan="1" colspan="1">0.12829</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">BCL2</td>
<td align="left" rowspan="1" colspan="1">0.84392</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">IGF1</td>
<td align="left" rowspan="1" colspan="1">0.48125</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">MAPK1</td>
<td align="left" rowspan="1" colspan="1">0.97740</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">PDGFB</td>
<td align="left" rowspan="1" colspan="1">0.51325</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">HGF</td>
<td align="left" rowspan="1" colspan="1">0.15429</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">FYN</td>
<td align="left" rowspan="1" colspan="1">0.95261</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">BRAF</td>
<td align="left" rowspan="1" colspan="1">0.37986</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">GRB2</td>
<td align="left" rowspan="1" colspan="1">0.83362</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">VEGFC</td>
<td align="left" rowspan="1" colspan="1">0.44556</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">SOS2</td>
<td align="left" rowspan="1" colspan="1">0.64114</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">BAD</td>
<td align="left" rowspan="1" colspan="1">0.36066</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">PDGFRB</td>
<td align="left" rowspan="1" colspan="1">0.79392</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">PDGFRA</td>
<td align="left" rowspan="1" colspan="1">0.67403</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">HRAS</td>
<td align="left" rowspan="1" colspan="1">0.37000</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">VEGFB</td>
<td align="left" rowspan="1" colspan="1">0.22218</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">XIAP</td>
<td align="left" rowspan="1" colspan="1">0.23878</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">SHC1</td>
<td align="left" rowspan="1" colspan="1">0.56594</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">BIRC3</td>
<td align="left" rowspan="1" colspan="1">0.75293</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">ELK1</td>
<td align="left" rowspan="1" colspan="1">0.58034</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
</tbody>
</table>
</alternatives><table-wrap-foot><fn id="nt102"><label/><p>• all the results were calculated by ARTP method with the significant SNPs (<italic>P</italic>&lt;0.05) in the loci-level associated analysis collected.</p></fn><fn id="nt103"><label/><p>• the significant <italic>P</italic> values were marked in the bold.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3b">
<title>Natural positive selection loci and related eQTL</title>
<p>On the basis of the web-based tool Haplotter, iHs values for all three different ethnic groups (ASN, CEU, and YRI) in HapMap phase II were obtained. Considering our Asian samples, iHs values in ASN were selected according to the number of SNP in the two data sets. In order to analyze the data comprehensively, we defined the threshold as 0.05. In addition, |iHs|&gt;1.65 was used in the next selection. Then, 26 SNPs came into view, which were mainly focused on two genes, EGFR (in the pathway) and MKRN2, located on chromosomes 7 and 16, respectively (<xref ref-type="table" rid="pone-0078254-t003">Table 3</xref>). The maximum values of |iHs| reached 2.967 for rs17172432 (EGFR) with cis-eQTL (<italic>P</italic> = 0.0424, JPT). In addition, the results suggested the association with PCa risk was mainly focused on EGFR. After selecting the potential natural selection loci, we identified the genes with selection in <xref ref-type="table" rid="pone-0078254-t004">Table 4</xref>. The genes were as follows: IGF1 (CEU), EGFR (ASN), ERBB2 (YRI), SHC1 (ASN) GRB2 (ASN and CEU), RAF1 (ASN), MAP2K1 (YRI), PTK2 (CEU), and PDGFB (ASN). With these haplotypes and gene analyses on the positive selection loci, the EGFR was identified again, so we suggested the gene might potentially play an important role in the development and progression of PCa.</p>
<table-wrap id="pone-0078254-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0078254.t003</object-id><label>Table 3</label><caption>
<title>The SNPs which were identified to be significances (<italic>P</italic>&lt;0.05) in the loci-level associated analysis and under nature positive selection (|iHS|&gt;1.65).</title>
</caption><alternatives><graphic id="pone-0078254-t003-3" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0078254.t003" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1">CHR</td>
<td align="left" rowspan="1" colspan="1">SNP</td>
<td align="left" rowspan="1" colspan="1">Gene</td>
<td align="left" rowspan="1" colspan="1">OR</td>
<td align="left" rowspan="1" colspan="1">L95</td>
<td align="left" rowspan="1" colspan="1">U95</td>
<td align="left" rowspan="1" colspan="1">P</td>
<td align="left" rowspan="1" colspan="1">iHs_ASN</td>
<td align="left" rowspan="1" colspan="1">iHs_CEU</td>
<td align="left" rowspan="1" colspan="1">iHs_YRI</td>
<td align="left" rowspan="1" colspan="1">Gene_ASN</td>
<td align="left" rowspan="1" colspan="1">Gene_CEU</td>
<td align="left" rowspan="1" colspan="1">Gene_YRI</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">7</td>
<td align="left" rowspan="1" colspan="1">rs11238349</td>
<td align="left" rowspan="1" colspan="1">EGFR</td>
<td align="left" rowspan="1" colspan="1">0.766</td>
<td align="left" rowspan="1" colspan="1">0.6078</td>
<td align="left" rowspan="1" colspan="1">0.9653</td>
<td align="left" rowspan="1" colspan="1">0.02387</td>
<td align="left" rowspan="1" colspan="1">−2.751</td>
<td align="left" rowspan="1" colspan="1">−1.532</td>
<td align="left" rowspan="1" colspan="1">NA</td>
<td align="left" rowspan="1" colspan="1"><bold>+</bold></td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">7</td>
<td align="left" rowspan="1" colspan="1">rs2302535</td>
<td align="left" rowspan="1" colspan="1">EGFR</td>
<td align="left" rowspan="1" colspan="1">0.7708</td>
<td align="left" rowspan="1" colspan="1">0.6121</td>
<td align="left" rowspan="1" colspan="1">0.9707</td>
<td align="left" rowspan="1" colspan="1">0.02693</td>
<td align="left" rowspan="1" colspan="1">−2.725</td>
<td align="left" rowspan="1" colspan="1">−1.503</td>
<td align="left" rowspan="1" colspan="1">NA</td>
<td align="left" rowspan="1" colspan="1"><bold>+</bold></td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">7</td>
<td align="left" rowspan="1" colspan="1">rs12535578</td>
<td align="left" rowspan="1" colspan="1">EGFR</td>
<td align="left" rowspan="1" colspan="1">0.7809</td>
<td align="left" rowspan="1" colspan="1">0.6206</td>
<td align="left" rowspan="1" colspan="1">0.9826</td>
<td align="left" rowspan="1" colspan="1">0.03486</td>
<td align="left" rowspan="1" colspan="1">−2.723</td>
<td align="left" rowspan="1" colspan="1">−1.734</td>
<td align="left" rowspan="1" colspan="1">NA</td>
<td align="left" rowspan="1" colspan="1"><bold>+</bold></td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">7</td>
<td align="left" rowspan="1" colspan="1">rs3800827</td>
<td align="left" rowspan="1" colspan="1">EGFR</td>
<td align="left" rowspan="1" colspan="1">0.801</td>
<td align="left" rowspan="1" colspan="1">0.6543</td>
<td align="left" rowspan="1" colspan="1">0.9806</td>
<td align="left" rowspan="1" colspan="1">0.03158</td>
<td align="left" rowspan="1" colspan="1">−2.538</td>
<td align="left" rowspan="1" colspan="1">−1.594</td>
<td align="left" rowspan="1" colspan="1">NA</td>
<td align="left" rowspan="1" colspan="1"><bold>+</bold></td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">7</td>
<td align="left" rowspan="1" colspan="1">rs984654</td>
<td align="left" rowspan="1" colspan="1">EGFR</td>
<td align="left" rowspan="1" colspan="1">0.8001</td>
<td align="left" rowspan="1" colspan="1">0.6579</td>
<td align="left" rowspan="1" colspan="1">0.9731</td>
<td align="left" rowspan="1" colspan="1">0.02558</td>
<td align="left" rowspan="1" colspan="1">−2.530</td>
<td align="left" rowspan="1" colspan="1">−1.498</td>
<td align="left" rowspan="1" colspan="1">NA</td>
<td align="left" rowspan="1" colspan="1"><bold>+</bold></td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">7</td>
<td align="left" rowspan="1" colspan="1">rs3735064</td>
<td align="left" rowspan="1" colspan="1">EGFR</td>
<td align="left" rowspan="1" colspan="1">0.7874</td>
<td align="left" rowspan="1" colspan="1">0.6429</td>
<td align="left" rowspan="1" colspan="1">0.9642</td>
<td align="left" rowspan="1" colspan="1">0.02077</td>
<td align="left" rowspan="1" colspan="1">−2.498</td>
<td align="left" rowspan="1" colspan="1">−1.635</td>
<td align="left" rowspan="1" colspan="1">−1.003</td>
<td align="left" rowspan="1" colspan="1"><bold>+</bold></td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">7</td>
<td align="left" rowspan="1" colspan="1">rs9642564</td>
<td align="left" rowspan="1" colspan="1">EGFR</td>
<td align="left" rowspan="1" colspan="1">0.8008</td>
<td align="left" rowspan="1" colspan="1">0.6535</td>
<td align="left" rowspan="1" colspan="1">0.9814</td>
<td align="left" rowspan="1" colspan="1">0.03226</td>
<td align="left" rowspan="1" colspan="1">−2.498</td>
<td align="left" rowspan="1" colspan="1">−1.635</td>
<td align="left" rowspan="1" colspan="1">NA</td>
<td align="left" rowspan="1" colspan="1"><bold>+</bold></td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">7</td>
<td align="left" rowspan="1" colspan="1">rs11766798</td>
<td align="left" rowspan="1" colspan="1">EGFR</td>
<td align="left" rowspan="1" colspan="1">0.8016</td>
<td align="left" rowspan="1" colspan="1">0.6539</td>
<td align="left" rowspan="1" colspan="1">0.9826</td>
<td align="left" rowspan="1" colspan="1">0.0333</td>
<td align="left" rowspan="1" colspan="1">−2.495</td>
<td align="left" rowspan="1" colspan="1">−0.906</td>
<td align="left" rowspan="1" colspan="1">NA</td>
<td align="left" rowspan="1" colspan="1"><bold>+</bold></td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">7</td>
<td align="left" rowspan="1" colspan="1">rs6978771</td>
<td align="left" rowspan="1" colspan="1">EGFR</td>
<td align="left" rowspan="1" colspan="1">0.793</td>
<td align="left" rowspan="1" colspan="1">0.6476</td>
<td align="left" rowspan="1" colspan="1">0.971</td>
<td align="left" rowspan="1" colspan="1">0.02475</td>
<td align="left" rowspan="1" colspan="1">−2.429</td>
<td align="left" rowspan="1" colspan="1">−1.804</td>
<td align="left" rowspan="1" colspan="1">NA</td>
<td align="left" rowspan="1" colspan="1"><bold>+</bold></td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">7</td>
<td align="left" rowspan="1" colspan="1">rs11773818</td>
<td align="left" rowspan="1" colspan="1">EGFR</td>
<td align="left" rowspan="1" colspan="1">0.8013</td>
<td align="left" rowspan="1" colspan="1">0.6663</td>
<td align="left" rowspan="1" colspan="1">0.9636</td>
<td align="left" rowspan="1" colspan="1">0.01856</td>
<td align="left" rowspan="1" colspan="1">−2.171</td>
<td align="left" rowspan="1" colspan="1">−0.908</td>
<td align="left" rowspan="1" colspan="1">NA</td>
<td align="left" rowspan="1" colspan="1"><bold>+</bold></td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">3</td>
<td align="left" rowspan="1" colspan="1">rs9818046</td>
<td align="left" rowspan="1" colspan="1">NA</td>
<td align="left" rowspan="1" colspan="1">0.7656</td>
<td align="left" rowspan="1" colspan="1">0.6098</td>
<td align="left" rowspan="1" colspan="1">0.9612</td>
<td align="left" rowspan="1" colspan="1">0.0214</td>
<td align="left" rowspan="1" colspan="1">−1.675</td>
<td align="left" rowspan="1" colspan="1">−0.236</td>
<td align="left" rowspan="1" colspan="1">0.343</td>
<td align="left" rowspan="1" colspan="1"><bold>+</bold></td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">7</td>
<td align="left" rowspan="1" colspan="1">rs3735062</td>
<td align="left" rowspan="1" colspan="1">EGFR</td>
<td align="left" rowspan="1" colspan="1">0.6426</td>
<td align="left" rowspan="1" colspan="1">0.4156</td>
<td align="left" rowspan="1" colspan="1">0.9934</td>
<td align="left" rowspan="1" colspan="1">0.04664</td>
<td align="left" rowspan="1" colspan="1">−1.653</td>
<td align="left" rowspan="1" colspan="1">NA</td>
<td align="left" rowspan="1" colspan="1">NA</td>
<td align="left" rowspan="1" colspan="1"><bold>+</bold></td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">7</td>
<td align="left" rowspan="1" colspan="1">rs17172432</td>
<td align="left" rowspan="1" colspan="1">EGFR</td>
<td align="left" rowspan="1" colspan="1">0.673</td>
<td align="left" rowspan="1" colspan="1">0.525</td>
<td align="left" rowspan="1" colspan="1">0.8626</td>
<td align="left" rowspan="1" colspan="1">0.001768</td>
<td align="left" rowspan="1" colspan="1">2.967</td>
<td align="left" rowspan="1" colspan="1">−0.416</td>
<td align="left" rowspan="1" colspan="1">0.457</td>
<td align="left" rowspan="1" colspan="1"><bold>+</bold></td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">7</td>
<td align="left" rowspan="1" colspan="1">rs17172434</td>
<td align="left" rowspan="1" colspan="1">EGFR</td>
<td align="left" rowspan="1" colspan="1">0.6899</td>
<td align="left" rowspan="1" colspan="1">0.5297</td>
<td align="left" rowspan="1" colspan="1">0.8984</td>
<td align="left" rowspan="1" colspan="1">0.005871</td>
<td align="left" rowspan="1" colspan="1">2.850</td>
<td align="left" rowspan="1" colspan="1">NA</td>
<td align="left" rowspan="1" colspan="1">0.020</td>
<td align="left" rowspan="1" colspan="1"><bold>+</bold></td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">15</td>
<td align="left" rowspan="1" colspan="1">rs6494584</td>
<td align="left" rowspan="1" colspan="1">NA</td>
<td align="left" rowspan="1" colspan="1">0.8549</td>
<td align="left" rowspan="1" colspan="1">0.7465</td>
<td align="left" rowspan="1" colspan="1">0.979</td>
<td align="left" rowspan="1" colspan="1">0.02338</td>
<td align="left" rowspan="1" colspan="1">2.233</td>
<td align="left" rowspan="1" colspan="1">NA</td>
<td align="left" rowspan="1" colspan="1">−0.050</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"><bold>+</bold></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">11</td>
<td align="left" rowspan="1" colspan="1">rs7115260</td>
<td align="left" rowspan="1" colspan="1">NA</td>
<td align="left" rowspan="1" colspan="1">0.1387</td>
<td align="left" rowspan="1" colspan="1">0.02398</td>
<td align="left" rowspan="1" colspan="1">0.8024</td>
<td align="left" rowspan="1" colspan="1">0.0274</td>
<td align="left" rowspan="1" colspan="1">2.161</td>
<td align="left" rowspan="1" colspan="1">1.318</td>
<td align="left" rowspan="1" colspan="1">1.331</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">3</td>
<td align="left" rowspan="1" colspan="1">rs2255648</td>
<td align="left" rowspan="1" colspan="1">MKRN2</td>
<td align="left" rowspan="1" colspan="1">0.7628</td>
<td align="left" rowspan="1" colspan="1">0.6026</td>
<td align="left" rowspan="1" colspan="1">0.9655</td>
<td align="left" rowspan="1" colspan="1">0.02431</td>
<td align="left" rowspan="1" colspan="1">2.104</td>
<td align="left" rowspan="1" colspan="1">1.158</td>
<td align="left" rowspan="1" colspan="1">0.365</td>
<td align="left" rowspan="1" colspan="1"><bold>+</bold></td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">3</td>
<td align="left" rowspan="1" colspan="1">rs1542848</td>
<td align="left" rowspan="1" colspan="1">MKRN2</td>
<td align="left" rowspan="1" colspan="1">0.6941</td>
<td align="left" rowspan="1" colspan="1">0.5314</td>
<td align="left" rowspan="1" colspan="1">0.9068</td>
<td align="left" rowspan="1" colspan="1">0.007408</td>
<td align="left" rowspan="1" colspan="1">2.008</td>
<td align="left" rowspan="1" colspan="1">0.323</td>
<td align="left" rowspan="1" colspan="1">−0.056</td>
<td align="left" rowspan="1" colspan="1"><bold>+</bold></td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">7</td>
<td align="left" rowspan="1" colspan="1">rs17172438</td>
<td align="left" rowspan="1" colspan="1">EGFR</td>
<td align="left" rowspan="1" colspan="1">0.6003</td>
<td align="left" rowspan="1" colspan="1">0.4153</td>
<td align="left" rowspan="1" colspan="1">0.8678</td>
<td align="left" rowspan="1" colspan="1">0.006644</td>
<td align="left" rowspan="1" colspan="1">1.912</td>
<td align="left" rowspan="1" colspan="1">−0.424</td>
<td align="left" rowspan="1" colspan="1">−0.453</td>
<td align="left" rowspan="1" colspan="1"><bold>+</bold></td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">7</td>
<td align="left" rowspan="1" colspan="1">rs17172436</td>
<td align="left" rowspan="1" colspan="1">EGFR</td>
<td align="left" rowspan="1" colspan="1">0.6598</td>
<td align="left" rowspan="1" colspan="1">0.4401</td>
<td align="left" rowspan="1" colspan="1">0.989</td>
<td align="left" rowspan="1" colspan="1">0.04405</td>
<td align="left" rowspan="1" colspan="1">1.912</td>
<td align="left" rowspan="1" colspan="1">NA</td>
<td align="left" rowspan="1" colspan="1">0.769</td>
<td align="left" rowspan="1" colspan="1"><bold>+</bold></td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">7</td>
<td align="left" rowspan="1" colspan="1">rs3735063</td>
<td align="left" rowspan="1" colspan="1">EGFR</td>
<td align="left" rowspan="1" colspan="1">0.638</td>
<td align="left" rowspan="1" colspan="1">0.4246</td>
<td align="left" rowspan="1" colspan="1">0.9586</td>
<td align="left" rowspan="1" colspan="1">0.0305</td>
<td align="left" rowspan="1" colspan="1">1.908</td>
<td align="left" rowspan="1" colspan="1">NA</td>
<td align="left" rowspan="1" colspan="1">NA</td>
<td align="left" rowspan="1" colspan="1"><bold>+</bold></td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">3</td>
<td align="left" rowspan="1" colspan="1">rs2633442</td>
<td align="left" rowspan="1" colspan="1">MKRN2</td>
<td align="left" rowspan="1" colspan="1">0.7542</td>
<td align="left" rowspan="1" colspan="1">0.5822</td>
<td align="left" rowspan="1" colspan="1">0.9771</td>
<td align="left" rowspan="1" colspan="1">0.03272</td>
<td align="left" rowspan="1" colspan="1">1.893</td>
<td align="left" rowspan="1" colspan="1">0.850</td>
<td align="left" rowspan="1" colspan="1">−0.811</td>
<td align="left" rowspan="1" colspan="1"><bold>+</bold></td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">3</td>
<td align="left" rowspan="1" colspan="1">rs2442802</td>
<td align="left" rowspan="1" colspan="1">MKRN2</td>
<td align="left" rowspan="1" colspan="1">0.7669</td>
<td align="left" rowspan="1" colspan="1">0.5926</td>
<td align="left" rowspan="1" colspan="1">0.9925</td>
<td align="left" rowspan="1" colspan="1">0.04365</td>
<td align="left" rowspan="1" colspan="1">1.893</td>
<td align="left" rowspan="1" colspan="1">0.850</td>
<td align="left" rowspan="1" colspan="1">−0.811</td>
<td align="left" rowspan="1" colspan="1"><bold>+</bold></td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">7</td>
<td align="left" rowspan="1" colspan="1">rs10488140</td>
<td align="left" rowspan="1" colspan="1">EGFR</td>
<td align="left" rowspan="1" colspan="1">0.7337</td>
<td align="left" rowspan="1" colspan="1">0.5399</td>
<td align="left" rowspan="1" colspan="1">0.997</td>
<td align="left" rowspan="1" colspan="1">0.04782</td>
<td align="left" rowspan="1" colspan="1">1.824</td>
<td align="left" rowspan="1" colspan="1">−0.463</td>
<td align="left" rowspan="1" colspan="1">−0.139</td>
<td align="left" rowspan="1" colspan="1"><bold>+</bold></td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">16</td>
<td align="left" rowspan="1" colspan="1">rs2005219</td>
<td align="left" rowspan="1" colspan="1">BOLA2</td>
<td align="left" rowspan="1" colspan="1">0.7858</td>
<td align="left" rowspan="1" colspan="1">0.6737</td>
<td align="left" rowspan="1" colspan="1">0.9166</td>
<td align="left" rowspan="1" colspan="1">0.002144</td>
<td align="left" rowspan="1" colspan="1">1.750</td>
<td align="left" rowspan="1" colspan="1">0.874</td>
<td align="left" rowspan="1" colspan="1">0.211</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">3</td>
<td align="left" rowspan="1" colspan="1">rs2454431</td>
<td align="left" rowspan="1" colspan="1">NA</td>
<td align="left" rowspan="1" colspan="1">0.743</td>
<td align="left" rowspan="1" colspan="1">0.5746</td>
<td align="left" rowspan="1" colspan="1">0.9608</td>
<td align="left" rowspan="1" colspan="1">0.02354</td>
<td align="left" rowspan="1" colspan="1">1.722</td>
<td align="left" rowspan="1" colspan="1">−0.017</td>
<td align="left" rowspan="1" colspan="1">−1.581</td>
<td align="left" rowspan="1" colspan="1"><bold>+</bold></td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">7</td>
<td align="left" rowspan="1" colspan="1">rs6958497</td>
<td align="left" rowspan="1" colspan="1">EGFR</td>
<td align="left" rowspan="1" colspan="1">2.64</td>
<td align="left" rowspan="1" colspan="1">1.119</td>
<td align="left" rowspan="1" colspan="1">6.227</td>
<td align="left" rowspan="1" colspan="1">0.02663</td>
<td align="left" rowspan="1" colspan="1">1.647</td>
<td align="left" rowspan="1" colspan="1">NA</td>
<td align="left" rowspan="1" colspan="1">0.962</td>
<td align="left" rowspan="1" colspan="1"><bold>+</bold></td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
</tbody>
</table>
</alternatives><table-wrap-foot><fn id="nt104"><label/><p>• the “+” stands for the genes under positive selection.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone-0078254-t004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0078254.t004</object-id><label>Table 4</label><caption>
<title>The condition of genes in the RTK/ERK pathway under positive selection among three different populations.</title>
</caption><alternatives><graphic id="pone-0078254-t004-4" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0078254.t004" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1">Gene</td>
<td align="left" rowspan="1" colspan="1">CEU</td>
<td align="left" rowspan="1" colspan="1">YRI</td>
<td align="left" rowspan="1" colspan="1">ASN</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">PDGFC</td>
<td align="left" rowspan="1" colspan="1">0.12713</td>
<td align="left" rowspan="1" colspan="1">0.643733</td>
<td align="left" rowspan="1" colspan="1">0.114897</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">PDGFD</td>
<td align="left" rowspan="1" colspan="1">0.257203</td>
<td align="left" rowspan="1" colspan="1">0.406681</td>
<td align="left" rowspan="1" colspan="1">0.753926</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">IGF1</td>
<td align="left" rowspan="1" colspan="1"><bold>0.067438</bold></td>
<td align="left" rowspan="1" colspan="1">0.54597</td>
<td align="left" rowspan="1" colspan="1">0.503402</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">HGF</td>
<td align="left" rowspan="1" colspan="1">0.448157</td>
<td align="left" rowspan="1" colspan="1">0.273572</td>
<td align="left" rowspan="1" colspan="1">0.420436</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">EGFR</td>
<td align="left" rowspan="1" colspan="1">0.527316</td>
<td align="left" rowspan="1" colspan="1">0.889825</td>
<td align="left" rowspan="1" colspan="1"><bold>0.07925</bold></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">PDGFRA</td>
<td align="left" rowspan="1" colspan="1">0.633894</td>
<td align="left" rowspan="1" colspan="1">0.889825</td>
<td align="left" rowspan="1" colspan="1">0.60804</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">ERBB2</td>
<td align="left" rowspan="1" colspan="1">0.633894</td>
<td align="left" rowspan="1" colspan="1">0.040607</td>
<td align="left" rowspan="1" colspan="1">0.60804</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">IGF1R</td>
<td align="left" rowspan="1" colspan="1">0.632913</td>
<td align="left" rowspan="1" colspan="1">0.755287</td>
<td align="left" rowspan="1" colspan="1">0.607936</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">PDGFRB</td>
<td align="left" rowspan="1" colspan="1">0.448157</td>
<td align="left" rowspan="1" colspan="1">0.761058</td>
<td align="left" rowspan="1" colspan="1">0.361076</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">FLT1</td>
<td align="left" rowspan="1" colspan="1">0.62966</td>
<td align="left" rowspan="1" colspan="1">0.641741</td>
<td align="left" rowspan="1" colspan="1">0.271252</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">FLT4</td>
<td align="left" rowspan="1" colspan="1">0.12713</td>
<td align="left" rowspan="1" colspan="1">0.889825</td>
<td align="left" rowspan="1" colspan="1">0.755444</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">KDR</td>
<td align="left" rowspan="1" colspan="1">0.787049</td>
<td align="left" rowspan="1" colspan="1">0.761058</td>
<td align="left" rowspan="1" colspan="1">0.755444</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">MET</td>
<td align="left" rowspan="1" colspan="1">0.633894</td>
<td align="left" rowspan="1" colspan="1">0.185004</td>
<td align="left" rowspan="1" colspan="1">0.755444</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">SHC1</td>
<td align="left" rowspan="1" colspan="1">0.633894</td>
<td align="left" rowspan="1" colspan="1">0.35688</td>
<td align="left" rowspan="1" colspan="1"><bold>0.045331</bold></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">GRB2</td>
<td align="left" rowspan="1" colspan="1"><bold>0.092378</bold></td>
<td align="left" rowspan="1" colspan="1">0.240116</td>
<td align="left" rowspan="1" colspan="1"><bold>0.014238</bold></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">SOS1</td>
<td align="left" rowspan="1" colspan="1">0.258804</td>
<td align="left" rowspan="1" colspan="1">0.643733</td>
<td align="left" rowspan="1" colspan="1">0.503402</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">HRAS</td>
<td align="left" rowspan="1" colspan="1">0.787049</td>
<td align="left" rowspan="1" colspan="1">0.35688</td>
<td align="left" rowspan="1" colspan="1">0.755444</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">RAF1</td>
<td align="left" rowspan="1" colspan="1">0.633894</td>
<td align="left" rowspan="1" colspan="1">0.273572</td>
<td align="left" rowspan="1" colspan="1"><bold>0.040149</bold></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">MAP2K1</td>
<td align="left" rowspan="1" colspan="1">0.528917</td>
<td align="left" rowspan="1" colspan="1"><bold>0.065686</bold></td>
<td align="left" rowspan="1" colspan="1">0.420436</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">BAD</td>
<td align="left" rowspan="1" colspan="1">0.187752</td>
<td align="left" rowspan="1" colspan="1">0.273572</td>
<td align="left" rowspan="1" colspan="1">0.420436</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">BCL2</td>
<td align="left" rowspan="1" colspan="1">0.231643</td>
<td align="left" rowspan="1" colspan="1">0.753039</td>
<td align="left" rowspan="1" colspan="1">0.270781</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">MAPK3</td>
<td align="left" rowspan="1" colspan="1">0.633894</td>
<td align="left" rowspan="1" colspan="1">0.761058</td>
<td align="left" rowspan="1" colspan="1">0.420436</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">MAPK1</td>
<td align="left" rowspan="1" colspan="1">0.633894</td>
<td align="left" rowspan="1" colspan="1">0.13459</td>
<td align="left" rowspan="1" colspan="1">0.60804</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">ELK1</td>
<td align="left" rowspan="1" colspan="1">NA</td>
<td align="left" rowspan="1" colspan="1">NA</td>
<td align="left" rowspan="1" colspan="1">NA</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">BRAF</td>
<td align="left" rowspan="1" colspan="1">0.386864</td>
<td align="left" rowspan="1" colspan="1">0.209827</td>
<td align="left" rowspan="1" colspan="1">0.755444</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">PTK2</td>
<td align="left" rowspan="1" colspan="1"><bold>0.008314</bold></td>
<td align="left" rowspan="1" colspan="1">0.27204</td>
<td align="left" rowspan="1" colspan="1">0.755444</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">FYN</td>
<td align="left" rowspan="1" colspan="1">0.210111</td>
<td align="left" rowspan="1" colspan="1">0.207937</td>
<td align="left" rowspan="1" colspan="1">0.60626</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">SOS2</td>
<td align="left" rowspan="1" colspan="1">0.633894</td>
<td align="left" rowspan="1" colspan="1">0.312085</td>
<td align="left" rowspan="1" colspan="1">0.60804</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">CCND1</td>
<td align="left" rowspan="1" colspan="1">0.386864</td>
<td align="left" rowspan="1" colspan="1">0.761058</td>
<td align="left" rowspan="1" colspan="1">0.214353</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">CCND2</td>
<td align="left" rowspan="1" colspan="1">0.633894</td>
<td align="left" rowspan="1" colspan="1">0.643733</td>
<td align="left" rowspan="1" colspan="1">0.503402</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">CCND3</td>
<td align="left" rowspan="1" colspan="1">0.528917</td>
<td align="left" rowspan="1" colspan="1">0.761058</td>
<td align="left" rowspan="1" colspan="1">0.114897</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">BIRC2</td>
<td align="left" rowspan="1" colspan="1">0.528917</td>
<td align="left" rowspan="1" colspan="1">0.406732</td>
<td align="left" rowspan="1" colspan="1">0.60804</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">BIRC3</td>
<td align="left" rowspan="1" colspan="1">0.528917</td>
<td align="left" rowspan="1" colspan="1">0.406732</td>
<td align="left" rowspan="1" colspan="1">0.60804</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">XIAP</td>
<td align="left" rowspan="1" colspan="1">NA</td>
<td align="left" rowspan="1" colspan="1">NA</td>
<td align="left" rowspan="1" colspan="1">NA</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">EGF</td>
<td align="left" rowspan="1" colspan="1">0.12713</td>
<td align="left" rowspan="1" colspan="1">0.273572</td>
<td align="left" rowspan="1" colspan="1">0.138348</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">PDGFA</td>
<td align="left" rowspan="1" colspan="1">NA</td>
<td align="left" rowspan="1" colspan="1">NA</td>
<td align="left" rowspan="1" colspan="1">NA</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">PDGFB</td>
<td align="left" rowspan="1" colspan="1">0.633894</td>
<td align="left" rowspan="1" colspan="1">0.406732</td>
<td align="left" rowspan="1" colspan="1"><bold>0.03816</bold></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">VEGFA</td>
<td align="left" rowspan="1" colspan="1">0.633894</td>
<td align="left" rowspan="1" colspan="1">0.468536</td>
<td align="left" rowspan="1" colspan="1">0.755444</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">VEGFB</td>
<td align="left" rowspan="1" colspan="1">0.169059</td>
<td align="left" rowspan="1" colspan="1">0.35688</td>
<td align="left" rowspan="1" colspan="1">0.420436</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">VEGFC</td>
<td align="left" rowspan="1" colspan="1">0.448157</td>
<td align="left" rowspan="1" colspan="1">0.761058</td>
<td align="left" rowspan="1" colspan="1">0.19174</td>
</tr>
</tbody>
</table>
</alternatives><table-wrap-foot><fn id="nt105"><label/><p>• On the basis of the haplotter the positive selections were estimated for almost all the genes in the pathway in which <italic>P</italic>&lt;0.1 was looked as the threshold.</p></fn><fn id="nt106"><label/><p>• the significant <italic>P</italic> values were marked in the bold.</p></fn></table-wrap-foot></table-wrap>
<p>eQTL analysis was conducted with the proposed SNPs according to the Sanger method based on three different databases: HapMapIII, MuTHER healthy female twins, and Geneva GenCord individuals. The positive results are presented in <xref ref-type="supplementary-material" rid="pone.0078254.s002">Table S2</xref>, in which the cis-eQTL and tran-eQTL with the related genes are offered. Significant associations were collected. The results indicated additional SNPs in the pathway might have both cis-regulation and trans-regulation in the genes themselves and nearby (rs11238349, rs17172438, rs984654, rs11773818, and rs17172432) (<xref ref-type="table" rid="pone-0078254-t005">Table 5</xref>). However, the functions could not be repeated in all the HapMap samples derived from similar lymphocytes, different cell types or twins, which suggested specific influences in the different samples.</p>
<table-wrap id="pone-0078254-t005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0078254.t005</object-id><label>Table 5</label><caption>
<title>The characteristics of the positive loci in our studies with different analysis.</title>
</caption><alternatives><graphic id="pone-0078254-t005-5" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0078254.t005" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1">SNP</td>
<td align="left" rowspan="1" colspan="1">Gene</td>
<td align="left" rowspan="1" colspan="1">Allele</td>
<td colspan="3" align="left" rowspan="1">Genotype</td>
<td align="left" rowspan="1" colspan="1">loci_iHS</td>
<td align="left" rowspan="1" colspan="1">gene_iHS</td>
<td align="left" rowspan="1" colspan="1">loci_based <italic>P</italic></td>
<td align="left" rowspan="1" colspan="1">gene_based <italic>P</italic></td>
<td align="left" rowspan="1" colspan="1">cis-eQTL</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">mm</td>
<td align="left" rowspan="1" colspan="1">Mm</td>
<td align="left" rowspan="1" colspan="1">MM</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">rs11238349</td>
<td align="left" rowspan="1" colspan="1">EGFR</td>
<td align="left" rowspan="1" colspan="1">A/G</td>
<td align="left" rowspan="1" colspan="1">21</td>
<td align="left" rowspan="1" colspan="1">362</td>
<td align="left" rowspan="1" colspan="1">1834</td>
<td align="left" rowspan="1" colspan="1">−2.751</td>
<td align="left" rowspan="1" colspan="1">0.07925</td>
<td align="left" rowspan="1" colspan="1">0.02387</td>
<td align="left" rowspan="1" colspan="1">0.12999</td>
<td align="left" rowspan="1" colspan="1">0.013(CEU)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">rs17172438</td>
<td align="left" rowspan="1" colspan="1">EGFR</td>
<td align="left" rowspan="1" colspan="1">T/C</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">151</td>
<td align="left" rowspan="1" colspan="1">2273</td>
<td align="left" rowspan="1" colspan="1">1.912</td>
<td align="left" rowspan="1" colspan="1">0.07925</td>
<td align="left" rowspan="1" colspan="1">0.006644</td>
<td align="left" rowspan="1" colspan="1">0.12999</td>
<td align="left" rowspan="1" colspan="1">0.0382(YRI)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">rs984654</td>
<td align="left" rowspan="1" colspan="1">EGFR</td>
<td align="left" rowspan="1" colspan="1">C/T</td>
<td align="left" rowspan="1" colspan="1">36</td>
<td align="left" rowspan="1" colspan="1">540</td>
<td align="left" rowspan="1" colspan="1">1848</td>
<td align="left" rowspan="1" colspan="1">−2.530</td>
<td align="left" rowspan="1" colspan="1">0.07925</td>
<td align="left" rowspan="1" colspan="1">0.02558</td>
<td align="left" rowspan="1" colspan="1">0.12999</td>
<td align="left" rowspan="1" colspan="1">10-4(LCL)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">rs11773818</td>
<td align="left" rowspan="1" colspan="1">EGFR</td>
<td align="left" rowspan="1" colspan="1">T/C</td>
<td align="left" rowspan="1" colspan="1">45</td>
<td align="left" rowspan="1" colspan="1">620</td>
<td align="left" rowspan="1" colspan="1">1759</td>
<td align="left" rowspan="1" colspan="1">−2.171</td>
<td align="left" rowspan="1" colspan="1">0.07925</td>
<td align="left" rowspan="1" colspan="1">0.01856</td>
<td align="left" rowspan="1" colspan="1">0.12999</td>
<td align="left" rowspan="1" colspan="1">0.0675(fibroblast)/&lt;10<sup>−4</sup>(LCL)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">rs17172432</td>
<td align="left" rowspan="1" colspan="1">EGFR</td>
<td align="left" rowspan="1" colspan="1">T/C</td>
<td align="left" rowspan="1" colspan="1">9</td>
<td align="left" rowspan="1" colspan="1">353</td>
<td align="left" rowspan="1" colspan="1">1991</td>
<td align="left" rowspan="1" colspan="1">2.967</td>
<td align="left" rowspan="1" colspan="1">0.07925</td>
<td align="left" rowspan="1" colspan="1">0.001768</td>
<td align="left" rowspan="1" colspan="1">0.12999</td>
<td align="left" rowspan="1" colspan="1">0.0424(JPT)</td>
</tr>
</tbody>
</table>
</alternatives><table-wrap-foot><fn id="nt107"><label/><p>• m, minor allele; M, major allele.</p></fn><fn id="nt108"><label/><p>• the iHS values are referred to be the ASN population.</p></fn><fn id="nt109"><label/><p>• the eQTL is based on the Sanger with three different databases: HapMapIII, MuTHER healthy female twins and Geneva GenCord individuals.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s4">
<title>Discussion</title>
<sec id="s4a">
<title>Description</title>
<p>PCa is a worldwide disease that causes enormous losses each year considering its high morbidity and mortality. Recently, many studies have been focused on the function of regulatory pathways in the development and progression of related diseases, especially for cancers, <xref ref-type="bibr" rid="pone.0078254-Wang1">[31]</xref>–<xref ref-type="bibr" rid="pone.0078254-Lamy1">[32]</xref>, which could provide a way for targeted therapy <xref ref-type="bibr" rid="pone.0078254-Peng1">[33]</xref>–<xref ref-type="bibr" rid="pone.0078254-Burris1">[34]</xref>. In this study, we proposed that the RTK/ERK pathway could influence various cancers, including PCa, when the relevant proteins are mutated. On the basis of this hypothesis, the association between this pathway and PCa risk was analyzed. Combined with positive selection, the eQTL method, SNP-level association analysis, and a gene-based pathway analysis, we described the essential status of the pathway with regard to PCa. Our results suggest the RTK/ERK pathway has the potential to be a key factor regulating the development and progression of PCa, as we had determined before <xref ref-type="bibr" rid="pone.0078254-Ning1">[17]</xref>. According to the analysis we conducted, many genes were said to be significant associated with PCa risk. After combining all the genes we proposed 4 genes (EGFR, ERBB2, PTK2, and RAF1) with five SNPs (rs11238349, rs17172438, rs984654, rs11773818, and rs17172432) as the key factors influencing PCa. In this study, it is suggested many genes in the pathway are significant, especially EGFR, ERBB2, PTK2, and RAF1, which were not only associated with PCa risk, but also under natural selection. This study was based on the natural selection theory to discover potential positive selection in the pathway associated with PCa risk and gave us new insights into studying the relationship between this pathway and the disease.</p>
</sec><sec id="s4b">
<title>Loci-genes analysis and prostate cancer</title>
<p>As one of the significant genes, EGFR was proven to be important in PCa risk. The gene located on Chr7p12 was also determined to be ERBB1, a member of the HER/ERBB/EGFR family of receptors. Recent studies had revealed its close relationship with cancers <xref ref-type="bibr" rid="pone.0078254-Seshacharyulu1">[35]</xref>–<xref ref-type="bibr" rid="pone.0078254-Choi1">[36]</xref>. Through both homo- and heterodimeric HER complexes, cell proliferation, motility, and invasion were induced. In addition, it was revealed that obstructing expression and activity of HER-family members could prevent human neoplasia <xref ref-type="bibr" rid="pone.0078254-Arteaga1">[37]</xref>. Therefore, specific anti-EGFR monoclonal antibodies could inhibit cell growth and downregulate the related genes, which could reduce the development of PCa <xref ref-type="bibr" rid="pone.0078254-Rezaiemanesh1">[38]</xref>. As the other member of the family, ERBB2, a known proto-oncogene located on the long arm of human chromosome 17 (17q12), is overexpressed in cancers such as breast cancer, with approximately 30% amplification or over-expression of the gene. The gene overexpression could drive aggressive disease, representing a potential therapeutic target <xref ref-type="bibr" rid="pone.0078254-Howe1">[39]</xref>–<xref ref-type="bibr" rid="pone.0078254-Tan1">[40]</xref>. Recent studies have suggested that EGFR or ERBB2 contribute to prostate cancer (PCa) progression by activating the androgen receptor (AR) under hormone-poor conditions <xref ref-type="bibr" rid="pone.0078254-Pignon1">[41]</xref>. In 2001, Chen L et al. <xref ref-type="bibr" rid="pone.0078254-Chen1">[42]</xref> suggested that dual EGFR/HER2 inhibition combined with androgen withdrawal therapy could sensitize prostate cancer cells to apoptosis. In addition, PTK2 was also suggested to be associated with cancer development. Known as focal adhesion kinase (FAK), PTK2 was a focal adhesion-associated protein kinase involved in cellular adhesion. Lacoste J et al. <xref ref-type="bibr" rid="pone.0078254-Lacoste1">[43]</xref> presented FAK as necessary for the cell motility of PCa and enhancing metastasis. Sumitomo M et al. <xref ref-type="bibr" rid="pone.0078254-Sumitomo1">[44]</xref> indicated neutral endopeptidase (NEP) could inhibit FAK phosphorylation on tyrosine, which contributes to the invasion and metastases in PC cells through multiple pathways. In addition, we proposed in the analysis that a well-known proto-oncogene, RAF1, might play a key role in carcinogenesis among humans <xref ref-type="bibr" rid="pone.0078254-Emuss1">[45]</xref>–<xref ref-type="bibr" rid="pone.0078254-Storm1">[46]</xref>. It is a member of the Raf kinase family of serine/threonine-specific protein kinases, in which its brethren kinase B-Raf was the major player in carcinogenesis in humans. Approximately 20% of all examined human tumor samples display a mutated B-Raf gene <xref ref-type="bibr" rid="pone.0078254-Forbes1">[47]</xref>. Recently, Ren et al. <xref ref-type="bibr" rid="pone.0078254-Ren1">[48]</xref> suggested the RAF gene might be the main contributor in the activation of the RAS/RAF/MEK/ERK pathway in Chinese PCa. Keller et al. <xref ref-type="bibr" rid="pone.0078254-Keller1">[49]</xref> and Escara-Wilke et al. <xref ref-type="bibr" rid="pone.0078254-EscaraWilke1">[50]</xref> said Raf kinase inhibitory protein (RKIP) could be a promising factor in therapy. In summary, we concluded from our analysis that four genes (EGFR, ERBB2, PTK2 and RAF1) undergoing positive selection might be important in the regulation of PCa development via various mechanisms. Combined with the close relationship between PCa and these genes, we suggested that these four genes might be key in the RTK/ERK pathway. Through adhesion, cell signaling transduction, regulation of related genes, and assisting gene-gene or protein-protein interactions, the development, progression, and prognosis of the cancers could be regulated. The four genes might be the most promising targets for therapy in the treatment of PCa, especially by virtue of their combined effects.</p>
<p>In this analysis, the four genes (EGFR, ERBB2, PTK2, and RAF1) we proposed were under natural selection, which supported the views we presented above. There are three different types of natural selections: positive selection, negative selection, and balancing selection. Different types of selection would guide the development or purification of the species, in which either positive or negative selection could be more important. At the level of loci and genes, we presented the conditions of evolution for the RTK/ERK pathway. According to their suggestive thresholds (|iHS|&gt;1.65), positive loci were selected. After combining the associated analysis and the eQTL method, five SNPs (rs11238349, rs17172438, rs984654, rs11773818, and rs17172432) were identified as the significant loci that might play a key role in the Pca risk. Tracking recent research, these loci were said to be the possible key factors in the cancer risk. In 2009, Dong et al. <xref ref-type="bibr" rid="pone.0078254-Dong1">[51]</xref> studied the role of growth, differentiation, and apoptosis genes in regulating the renal cancer, which implied the rs11238349 in the EGFR might be statistically significantly associated with risk of renal cancer. At the same time, Hong et al. <xref ref-type="bibr" rid="pone.0078254-Hong1">[52]</xref> presented the potential significant association in the loci of EGFR (rs11773818 and rs17172432) and breast cancer risk, although without replication, in their stage II analysis. Considering the relationship of these SNPs with other cancers and the function of angiogenesis for the EGFR gene, we inferred that the SNPs we proposed might be associated with the metastasis of Pca to the kidney, breast and other viscera.</p>
<p>With the natural selection effects, the four genes seemed to be more important in regulating the development and progression of Pca based on human population analysis using linkage disequilibrium (LD)-based methods. Explanations for the development of PCa might be associated with evolution at the gene- and locus-level. In addition, combined with the gene-based pathway analysis and molecular evolution method, we did not only explain the key role of the pathway in the development of PCa, but also gained new insight into the potential role of molecular evolution in the pathway.</p>
</sec><sec id="s4c">
<title>Limitation</title>
<p>The presented study combining various analyses has some limitations. First, there are a lot of criteria to evaluate natural selection in a population. As just one of these measurements, iHs might be limited in the estimation. Second, the eQTL and positive selection were based on the available databases, which made it difficult to avoid deficiencies in the results. Finally, every statistical analysis should confirm the deviations. So the real association needs further research.</p>
</sec></sec><sec id="s5">
<title>Conclusions</title>
<p>In conclusion, prostate cancer is a worldwide disease that brings about inestimable losses for health and the economy. The RTKs-ERK pathway was said to be an important link in this cancer's development and progression. Combining natural selection, gene-based pathway analysis, and other associated analysis, we proposed that the pathway was significantly associated with PCa risk, in which the mutation of EGFR, ERBB2, PTK2, RAF1, and related SNPs in the genes might be the key link in the evolution of the cancer. However, given that the specific locus in the EGFR with positive selection was located in a non-functional intron, the real function of this intron in the evolution of cancers requires further attention.</p>
</sec><sec id="s6">
<title>Supporting Information</title>
<supplementary-material id="pone.0078254.s001" mimetype="application/msword" xlink:href="info:doi/10.1371/journal.pone.0078254.s001" position="float" xlink:type="simple"><label>Table S1</label><caption>
<p><bold>The results of association analysis for Pca risk on the SNPs-level with logistic regression model adjusting for age.</bold></p>
<p>(DOC)</p>
</caption></supplementary-material><supplementary-material id="pone.0078254.s002" mimetype="application/msword" xlink:href="info:doi/10.1371/journal.pone.0078254.s002" position="float" xlink:type="simple"><label>Table S2</label><caption>
<p><bold>Expression of quantitative trait loci (eQTLs) analysis with Geneva in three different databases (HapMapIII, MuTHER healthy female twins and Geneva GenCord individuals).</bold> *the results presented in the tables were significant collecting from the total eQTLs analysis for all SNPs in <xref ref-type="table" rid="pone-0078254-t003">table 3</xref>.</p>
<p>(DOC)</p>
</caption></supplementary-material></sec></body>
<back>
<ack>
<p>We thank the Chinese Consortium for Prostate Cancer Genetics (ChinaPCa) for providing the original data in our study. The Chinese Consortium for Prostate Cancer Genetics is an institution which mainly studies the prostate cancers among the Chinese.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pone.0078254-Parkin1"><label>1</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Parkin</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Bray</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Ferlay</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Pisani</surname><given-names>P</given-names></name> (<year>2005</year>) <article-title>Global cancer statistics, 2002</article-title>. <source>CA Cancer J Clin</source> <volume>55</volume>: <fpage>174</fpage>–<lpage>178</lpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-Jemal1"><label>2</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jemal</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Siegel</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Ward</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Hao</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>J</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Cancer statistics, 2009</article-title>. <source>CA Cancer J Clin</source> <volume>59</volume>: <fpage>225</fpage>–<lpage>249</lpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-Siegel1"><label>3</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Siegel</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Naishadham</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Jemal</surname><given-names>A</given-names></name> (<year>2012</year>) <article-title>Cancer Statistics, 2012</article-title>. <source>CA Cancer J Clin</source> <volume>62</volume>: <fpage>10</fpage>–<lpage>29</lpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-Jemal2"><label>4</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jemal</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Siegel</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Ward</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Hao</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>J</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title>Cancer statistics, 2008</article-title>. <source>CA Cancer J Clin</source> <volume>58</volume>: <fpage>71</fpage>–<lpage>96</lpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-Siegel2"><label>5</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Siegel</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Naishadham</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Jemal</surname><given-names>A</given-names></name> (<year>2013</year>) <article-title>Cancer Statistics, 2013</article-title>. <source>CA Cancer J Clin</source> <volume>63</volume>: <fpage>11</fpage>–<lpage>30</lpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-Ferlay1"><label>6</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ferlay</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Parkin</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Steliarova-Foucher</surname><given-names>E</given-names></name> (<year>2010</year>) <article-title>Estimates of cancer incidence and mortality in Europe in 2008</article-title>. <source>Eur J Cancer</source> <volume>46</volume>: <fpage>765</fpage>–<lpage>781</lpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-Shih1"><label>7</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shih</surname><given-names>MC</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>JY</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>YC</given-names></name>, <name name-style="western"><surname>Jan</surname><given-names>YH</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>BM</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer</article-title>. <source>Oncogene</source> <volume>31</volume>: <fpage>2389</fpage>–<lpage>2400</lpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-Zhao1"><label>8</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zhao</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Cai</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Qiu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Liao</surname><given-names>B</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>MicroRNA-221 Induces Cell Survival and Cisplatin Resistance through PI3K/Akt Pathway in Human Osteosarcoma</article-title>. <source>PLOS ONE</source> <volume>8</volume> (<issue>1</issue>) <fpage>e53906</fpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-Jung1"><label>9</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jung</surname><given-names>HY</given-names></name>, <name name-style="western"><surname>Joo</surname><given-names>HJ</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>JK</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>YH</given-names></name> (<year>2012</year>) <article-title>The Blocking of c-Met Signaling Induces Apoptosis through the Increase of p53 Protein in Lung Cancer</article-title>. <source>Cancer Res Treat</source> <volume>44</volume>: <fpage>251</fpage>–<lpage>261</lpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-McKay1"><label>10</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>McKay</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Morrison</surname><given-names>DK</given-names></name> (<year>2007</year>) <article-title>Integrating signals from RTKs to ERK/MAPK</article-title>. <source>Oncogene</source> <volume>26</volume>: <fpage>3113</fpage>–<lpage>3121</lpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-Kim1"><label>11</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kim</surname><given-names>HJ</given-names></name>, <name name-style="western"><surname>Bar-Sagi</surname><given-names>D</given-names></name> (<year>2004</year>) <article-title>Modulation of signalling by Sprouty: a developing story</article-title>. <source>Nat Rev Mol Cell Biol</source> <volume>5</volume>: <fpage>441</fpage>–<lpage>450</lpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-Malumbres1"><label>12</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Malumbres</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Barbacid</surname><given-names>M</given-names></name> (<year>2003</year>) <article-title>RAS oncogenes: the first 30 years</article-title>. <source>Nat Rev Cancer</source> <volume>3</volume>: <fpage>459</fpage>–<lpage>465</lpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-Orton1"><label>13</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Orton</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Sturm</surname><given-names>OE</given-names></name>, <name name-style="western"><surname>Vyshemirsky</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Calder</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Gilbert</surname><given-names>DR</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>Computational modelling of the receptor-tyrosine-kinase-activated MAPK pathway</article-title>. <source>Biochem J</source> <volume>392</volume>: <fpage>249</fpage>–<lpage>261</lpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-Pawson1"><label>14</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pawson</surname><given-names>T</given-names></name> (<year>1995</year>) <article-title>Protein modules and signalling networks</article-title>. <source>Nature</source> <volume>373</volume>: <fpage>573</fpage>–<lpage>580</lpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-Caraglia1"><label>15</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Caraglia</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Marra</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Leonetti</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Meo</surname><given-names>G</given-names></name>, <name name-style="western"><surname>D'Alessandro</surname><given-names>AM</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation</article-title>. <source>J Cell Physiol</source> <volume>211</volume>: <fpage>533</fpage>–<lpage>543</lpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-Milone1"><label>16</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Milone</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Pucci</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Bruzzese</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Carbone</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Piro</surname><given-names>G</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells</article-title>. <source>Cell Death Dis</source> <volume>4</volume>: <fpage>e641</fpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-Ning1"><label>17</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ning</surname><given-names>QY</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>JZ</given-names></name>, <name name-style="western"><surname>Zang</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Liang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>YL</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Key pathways involved in prostate cancer based on gene set enrichment analysis and meta-analysis</article-title>. <source>Genet Mol Res</source> <volume>10</volume>: <fpage>3856</fpage>–<lpage>3887</lpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-Kelley1"><label>18</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kelley</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Turkheimer</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Haney</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Swanson</surname><given-names>WJ</given-names></name> (<year>2009</year>) <article-title>Targeted resequencing of two genes, RAGE and POLL, confirms findings from a genome-wide scan for adaptive evolution and provides evidence for positive selection in additional populations</article-title>. <source>Hum Mol Genet</source> <volume>18</volume>: <fpage>779</fpage>–<lpage>784</lpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-AcuaAlonzo1"><label>19</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Acuña-Alonzo</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Flores-Dorantes</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Kruit</surname><given-names>JK</given-names></name>, <name name-style="western"><surname>Villarreal-Molina</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Arellano-Campos</surname><given-names>O</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>A functional ABCA1 gene variant is associated with low HDL-cholesterol levels and shows evidence of positive selection in Native Americans</article-title>. <source>Hum Mol Genet</source> <volume>19</volume>: <fpage>2877</fpage>–<lpage>2885</lpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-Xu1"><label>20</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Mo</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Ye</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>F</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Genome-wide association study in Chinese men identifies two new prostate cancer risk loci at 9q31.2 and 19q13.4</article-title>. <source>Nat Genet</source> <volume>44</volume>: <fpage>1231</fpage>–<lpage>1235</lpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-International1"><label>21</label>
<mixed-citation publication-type="journal" xlink:type="simple"><collab xlink:type="simple">International HapMap Consortium</collab> (<year>2005</year>) <article-title>A haplotype map of the human genome</article-title>. <source>Nature</source> <volume>437</volume>: <fpage>1299</fpage>–<lpage>1320</lpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-Stephens1"><label>22</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Stephens</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Scheet</surname><given-names>P</given-names></name> (<year>2005</year>) <article-title>Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation</article-title>. <source>Am J Hum Genet</source> <volume>76</volume>: <fpage>449</fpage>–<lpage>462</lpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-Voight1"><label>23</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Voight</surname><given-names>BF</given-names></name>, <name name-style="western"><surname>Kudaravalli</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Wen</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Pritchard</surname><given-names>JK</given-names></name> (<year>2006</year>) <article-title>A Map of Recent Positive Selection in the Human Genome</article-title>. <source>PLoS Biol</source> <volume>4</volume>: <fpage>e72</fpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-Purcell1"><label>24</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Purcell</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Neale</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Todd-Brown</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Thomas</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Ferreira</surname><given-names>MA</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>PLINK: a tool set for whole-genome association and population-based linkage analyses</article-title>. <source>Am J Hum Genet</source> <volume>81</volume>: <fpage>559</fpage>–<lpage>575</lpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-Yu1"><label>25</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yu</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Bergen</surname><given-names>AW</given-names></name>, <name name-style="western"><surname>Pfeiffer</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Rosenberg</surname><given-names>PS</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Pathway analysis by adaptive combination of P-values</article-title>. <source>Genet Epidemiol</source> <volume>33</volume>: <fpage>700</fpage>–<lpage>709</lpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-Dudbridge1"><label>26</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dudbridge</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Koeleman</surname><given-names>BP</given-names></name> (<year>2003</year>) <article-title>Rank truncated product of P-values, with application to genomewide association scans</article-title>. <source>Genet Epidemiol</source> <volume>25</volume>: <fpage>360</fpage>–<lpage>366</lpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-Raj1"><label>27</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Raj</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Shulman</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Keenan</surname><given-names>BT</given-names></name>, <name name-style="western"><surname>Chibnik</surname><given-names>LB</given-names></name>, <name name-style="western"><surname>Evans</surname><given-names>DA</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Alzheimer Disease Susceptibility Loci: Evidence for a Protein Network under Natural Selection</article-title>. <source>Am J Hum Genet</source> <volume>90</volume>: <fpage>720</fpage>–<lpage>726</lpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-Metspalu1"><label>28</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Metspalu</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Romero</surname><given-names>IG</given-names></name>, <name name-style="western"><surname>Yunusbayev</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Chaubey</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Mallick</surname><given-names>CB</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Shared and Unique Components of Human Population Structure and Genome-Wide Signals of Positive Selection in South Asia</article-title>. <source>Am J Hum Genet</source> <volume>89</volume>: <fpage>731</fpage>–<lpage>744</lpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-Nash1"><label>29</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nash</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Nair</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Mayxay</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Newton</surname><given-names>PN</given-names></name>, <name name-style="western"><surname>Guthmann</surname><given-names>JP</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>Selection strength and hitchhiking around two anti-malarial resistance genes</article-title>. <source>Proc Biol Sci</source> <volume>272</volume>: <fpage>1153</fpage>–<lpage>1161</lpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-Sabeti1"><label>30</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sabeti</surname><given-names>PC</given-names></name>, <name name-style="western"><surname>Reich</surname><given-names>DE</given-names></name>, <name name-style="western"><surname>Higgins</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Levine</surname><given-names>HZ</given-names></name>, <name name-style="western"><surname>Richter</surname><given-names>DJ</given-names></name>, <etal>et al</etal>. (<year>2002</year>) <article-title>Detecting recent positive selection in the human genome from haplotype structure</article-title>. <source>Nature</source> <volume>419</volume>: <fpage>832</fpage>–<lpage>837</lpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-Wang1"><label>31</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wang</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Ding</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Jing</surname><given-names>R</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>APRIL Induces Tumorigenesis and Metastasis of Colorectal Cancer Cells via Activation of the PI3K/Akt Pathway</article-title>. <source>PLoS One</source> <volume>8</volume>: <fpage>e55298</fpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-Lamy1"><label>32</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lamy</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Herz</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Lutz-Bonengel</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hertrampf</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Márton</surname><given-names>MR</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>The MAPK pathway signals telomerase modulation in response to isothiocyanate-induced DNA damage of human liver cancer cells</article-title>. <source>PLoS One</source> <volume>8</volume>: <fpage>e53240</fpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-Peng1"><label>33</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Peng</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Schwarz</surname><given-names>RE</given-names></name> (<year>2013</year>) <article-title>Pancreatic Neuroendocrine Tumors: Signal Pathways and Targeted Therapies</article-title>. <source>Curr Mol Med</source> <volume>13</volume>: <fpage>333</fpage>–<lpage>339</lpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-Burris1"><label>34</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Burris</surname><given-names>HA</given-names><suffix>3rd</suffix></name> (<year>2013</year>) <article-title>Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway</article-title>. <source>Cancer Chemother Pharmacol</source> <volume>71</volume>: <fpage>829</fpage>–<lpage>842</lpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-Seshacharyulu1"><label>35</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Seshacharyulu</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Ponnusamy</surname><given-names>MP</given-names></name>, <name name-style="western"><surname>Haridas</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Jain</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ganti</surname><given-names>AK</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Targeting the EGFR signaling pathway in cancer therapy</article-title>. <source>Expert Opin Ther Targets</source> <volume>16</volume>: <fpage>15</fpage>–<lpage>31</lpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-Choi1"><label>36</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Choi</surname><given-names>BK</given-names></name>, <name name-style="western"><surname>Fan</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Deng</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>N</given-names></name>, <name name-style="western"><surname>An</surname><given-names>Z</given-names></name> (<year>2012</year>) <article-title>ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells</article-title>. <source>Cancer Med</source> <volume>1</volume>: <fpage>28</fpage>–<lpage>38</lpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-Arteaga1"><label>37</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Arteaga</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Moulder</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>Yakes</surname><given-names>FM</given-names></name> (<year>2002</year>) <article-title>HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer</article-title>. <source>Semin Oncol</source> <volume>29</volume>: <fpage>4</fpage>–<lpage>10</lpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-Rezaiemanesh1"><label>38</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rezaiemanesh</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Majidi</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Baradaran</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Movasaghpour</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Nakhlband</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Impacts of anti-EGFR monoclonal antibody in prostate cancer PC3 cells</article-title>. <source>Hum Antibodies</source> <volume>19</volume>: <fpage>63</fpage>–<lpage>70</lpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-Howe1"><label>39</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Howe</surname><given-names>LR</given-names></name>, <name name-style="western"><surname>Brown</surname><given-names>PH</given-names></name> (<year>2011</year>) <article-title>Targeting the HER/EGFR/ErbB Family to Prevent Breast Cancer</article-title>. <source>Cancer Prev Res (Phila)</source> <volume>4</volume>: <fpage>1149</fpage>–<lpage>1157</lpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-Tan1"><label>40</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tan</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>D</given-names></name> (<year>2007</year>) <article-title>Molecular mechanisms of erbB2-mediated breast cancer chemoresistance</article-title>. <source>Adv Exp Med Biol</source> <volume>608</volume>: <fpage>119</fpage>–<lpage>129</lpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-Pignon1"><label>41</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pignon</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Koopmansch</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Nolens</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Delacroix</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Waltregny</surname><given-names>D</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Androgen receptor controls EGFR and ERBB2 gene expression at different levels in prostate cancer cell lines</article-title>. <source>Cancer Res</source> <volume>69</volume>: <fpage>2941</fpage>–<lpage>2949</lpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-Chen1"><label>42</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Mooso</surname><given-names>BA</given-names></name>, <name name-style="western"><surname>Jathal</surname><given-names>MK</given-names></name>, <name name-style="western"><surname>Madhav</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>SD</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3</article-title>. <source>Clin Cancer Res</source> <volume>17</volume>: <fpage>6218</fpage>–<lpage>6228</lpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-Lacoste1"><label>43</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lacoste</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Aprikian</surname><given-names>AG</given-names></name>, <name name-style="western"><surname>Chevalier</surname><given-names>S</given-names></name> (<year>2005</year>) <article-title>Focal adhesion kinase is required for bombesin-induced prostate cancer cell motility</article-title>. <source>Mol Cell Endocrinol</source> <volume>235</volume>: <fpage>51</fpage>–<lpage>61</lpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-Sumitomo1"><label>44</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sumitomo</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Walburg</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Dai</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Geng</surname><given-names>Y</given-names></name>, <etal>et al</etal>. (<year>2000</year>) <article-title>Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling</article-title>. <source>J Clin Invest</source> <volume>106</volume>: <fpage>1399</fpage>–<lpage>1407</lpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-Emuss1"><label>45</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Emuss</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Garnett</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Mason</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Marais</surname><given-names>R</given-names></name> (<year>2005</year>) <article-title>Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF</article-title>. <source>Cancer Res</source> <volume>65</volume>: <fpage>9719</fpage>–<lpage>9726</lpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-Storm1"><label>46</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Storm</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Rapp</surname><given-names>UR</given-names></name> (<year>1993</year>) <article-title>Oncogene activation: c-raf-1 gene mutations in experimental and naturally occurring tumors”</article-title>. <source>Toxicol Lett</source> <volume>67</volume>: <fpage>201</fpage>–<lpage>210</lpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-Forbes1"><label>47</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Forbes</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Bindal</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Bamford</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Cole</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Kok</surname><given-names>CY</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer</article-title>. <source>Nucleic Acids Res</source> <volume>39</volume> (<issue>Database issue</issue>) <fpage>D945</fpage>–<lpage>50</lpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-Ren1"><label>48</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ren</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Mao</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Stankiewicz</surname><given-names>E</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Identification of frequent BRAF copy number gain and alterations of RAF genes in Chinese prostate cancer</article-title>. <source>Genes Chromosomes Cancer</source> <volume>51</volume>: <fpage>1014</fpage>–<lpage>1023</lpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-Keller1"><label>49</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Keller</surname><given-names>ET</given-names></name> (<year>2011</year>) <article-title>Role of Raf Kinase Inhibitor Protein in Pathophysiology of Prostate Cancer</article-title>. <source>For Immunopathol Dis Therap</source> <volume>2</volume>: <fpage>89</fpage>–<lpage>94</lpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-EscaraWilke1"><label>50</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Escara-Wilke</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Yeung</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Keller</surname><given-names>ET</given-names></name> (<year>2012</year>) <article-title>Raf kinase inhibitor protein (RKIP) in cancer</article-title>. <source>Cancer Metastasis Rev</source> <volume>31</volume>: <fpage>615</fpage>–<lpage>620</lpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-Dong1"><label>51</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dong</surname><given-names>LM</given-names></name>, <name name-style="western"><surname>Brennan</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Karami</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hung</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Menashe</surname><given-names>I</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>An analysis of growth, differentiation and apoptosis genes with risk of renal cancer</article-title>. <source>PLoS One Mar</source> <volume>4</volume>: <fpage>e4895</fpage>.</mixed-citation>
</ref>
<ref id="pone.0078254-Hong1"><label>52</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hong</surname><given-names>YS</given-names></name>, <name name-style="western"><surname>Deming</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>YT</given-names></name>, <name name-style="western"><surname>Long</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Shu</surname><given-names>XO</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>A two-stage case-control study of EGFR polymorphisms and breast cancer risk</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source> <volume>18</volume>: <fpage>680</fpage>–<lpage>683</lpage>.</mixed-citation>
</ref>
</ref-list></back>
</article>